ANA-12

A selective antagonist of the TrkB receptor

ANA-12 is a small molecule that acts as a selective antagonist of the TrkB receptor, which is the main receptor for BDNF. It is used primarily in research to study the role of TrkB in various physiological and pathological processes.

Mechanism of Action

ANA-12 functions by binding to the TrkB receptor and inhibiting its activation by BDNF. This inhibition prevents the downstream signaling pathways that are typically activated by TrkB, such as the PI3K/AKT and MAPK/ERK pathways. These pathways are involved in cell survival, growth, and differentiation.

Research Applications

ANA-12 is used in various research settings to explore the role of TrkB in:

• Neuroplasticity
• Neuroprotection
• Depression and anxiety
• Cognitive function

By blocking TrkB, researchers can study the effects of reduced BDNF signaling in these contexts.

Potential Therapeutic Uses

While primarily a research tool, ANA-12 has potential therapeutic implications in conditions where TrkB signaling is dysregulated, such as:

• Neurodegenerative diseases
• Cancer
• Mood disorders

Safety and Toxicity

The safety profile of ANA-12 is still under investigation. As with many research chemicals, its effects in humans are not fully understood, and it is not approved for clinical use.

Chemical Properties

ANA-12 is a small molecule with a specific structure that allows it to selectively bind to the TrkB receptor. Its chemical properties are designed to optimize its ability to cross the blood-brain barrier and exert its effects in the central nervous system.

Related Pages

• Tropomyosin receptor kinase B
• Brain-derived neurotrophic factor
• Neurotrophin
• Signal transduction

Gallery

• 
  Structure of ANA-12